Thyrocare Technologies Limited
All news and filings related to Thyrocare Technologies Limited.
View all news & filings- Low impact
Thyrocare Technologies Limited: Newspaper Publication for Postal Ballot Notice
Thyrocare Technologies Limited has published newspaper advertisements regarding its Postal Ballot Notice in "Business Standard" and "Navshakti". The publication confirms the completion of sending notices and the start of the e-voting period.
Read the summary - Medium impact
Thyrocare seeks shareholder approval for land purchase & divestment of subsidiary
Thyrocare is seeking shareholder approval for two key resolutions. The first is to purchase land and buildings from its subsidiary, Nueclear Healthcare Limited (NHL), for ₹20.59 crore. The second is to divest its entire stake in NHL to Trovera Healthcare Private Limited for approximately ₹141.40 crore. E-voting will be open from September 30 to October 29, 2026.
Read the summary - Low impact
Thyrocare Grants 1,92,000 Stock Options to Employees
Thyrocare Technologies Limited granted 1,92,000 employee stock options with an exercise price of ₹10 per option. One-third of options vest annually over three years, subject to continued employment. Employees can exercise vested options within seven years.
Read the summary - Low impact
Thyrocare Technologies Closes Trading Window From Oct 1, 2026, For Q2 FY27 Results
Thyrocare Technologies will close its trading window from October 1, 2026. The window will reopen 48 hours after the declaration of un-audited financial results for the quarter and half year ended September 30, 2026. The board meeting date for considering these results will be announced later.
Read the summary - High impact
Thyrocare to Sell Entire Stake in Nueclear Healthcare for ₹141.4 Crore
Thyrocare will sell its entire stake in subsidiary Nueclear Healthcare (NHL) to Trovera for ₹141.40 crore. The deal includes ₹59.50 crore in preference shares and ₹81.90 crore in cash. Thyrocare will also buy back properties from NHL for ₹20.59 crore. The sale is expected to complete by November 30, 2026, subject to shareholder approval.
Read the summary - Medium impact
Thyrocare to Sell Entire Stake in Nueclear Healthcare for ₹141.4 Crore
Thyrocare will sell its entire stake in subsidiary Nueclear Healthcare (NHL) to Trovera Healthcare for ₹141.4 crore. The deal includes ₹59.5 crore in Trovera CCPS and ₹81.9 crore in cash. Thyrocare will also buy NHL's Gurugram and Hyderabad properties for ₹20.59 crore. The transaction is subject to shareholder approval and expected completion by November 30, 2026.
Read the summary - Medium impact
Thyrocare to Sell Entire Stake in Nueclear Healthcare for ₹141.4 Crore
Thyrocare Technologies will sell its entire stake in Nueclear Healthcare (NHL) to Trovera Healthcare for ₹141.4 crore. The deal includes ₹59.5 crore in CCPS and ₹81.9 crore in cash. Thyrocare will also buy NHL's properties for ₹20.59 crore. The transaction is expected to be completed by November 30, 2026, subject to shareholder approval.
Read the summary - High impact
API Holdings Completes Amalgamation with Docon, Acquires 51.02% of Thyrocare
API Holdings Limited completed the amalgamation of Docon Technologies Private Limited on September 03, 2026. This resulted in API Holdings acquiring 8,12,00,000 equity shares, representing 51.02% of Thyrocare Technologies Limited's paid-up share capital. The NCLT sanctioned the scheme on August 31, 2026.
Read the summary - Low impact
Thyrocare Technologies Limited: Notice of Newspaper Publication
Thyrocare Technologies Limited has published newspaper advertisements regarding the transfer of equity shares to the Investor Education and Protection Fund (IEPF). Shareholders are advised to claim unpaid dividends and shares before the specified deadlines to prevent transfer to the IEPF.
Read the summary - Medium impact
Thyrocare Technologies: NCLT Sanctions Amalgamation of Docon with API Holdings
NCLT has sanctioned the amalgamation of Docon Technologies with API Holdings. Docon's 51.02% stake (8,12,00,000 shares) in Thyrocare Technologies will vest with API. The promoter group's total shareholding remains 51.02%.
Read the summary - Low impact
Thyrocare: API Holdings Fully Repays ₹1700 Crore NCDs, Share Pledge Released
API Holdings Limited has fully redeemed and repaid its Non-Convertible Debentures (NCDs) aggregating ₹1,700 crore. This repayment has led to the complete release of the pledge over 60.92% of Thyrocare Technologies Limited's equity shares held by Docon Technologies Private Limited. A No-Dues certificate was issued on August 19, 2026.
Read the summary - Medium impact
Thyrocare Promoter Docon Technologies Releases Pledge on 7.94 Cr Shares
Docon Technologies Private Limited, promoter of Thyrocare Technologies Limited, has released its pledge over 7,94,69,696 equity shares. This action follows the full repayment of ₹10,500 million (1050 crore) in Non-Convertible Debentures by API Holdings Limited. Consequently, Docon's entire shareholding in Thyrocare is now free from encumbrance.
Read the summary - Medium impact
Thyrocare Promoter Docon Sells 9.90% Stake for ₹7,000 Crore
Docon Technologies Private Limited, a promoter of Thyrocare, sold 1,57,69,696 equity shares, representing 9.90% of the company's capital, on August 13, 2026. Promoter shareholding decreased from 60.92% to 51.02%. Docon remains a promoter.
Read the summary - Medium impact
Thyrocare Promoter Docon Tech Releases Pledge on 1.75 Cr Shares
Docon Technologies Private Limited, a promoter of Thyrocare Technologies Limited, has announced the release of a pledge on 1,75,00,000 equity shares. The release occurred on August 11, 2026. These shares were pledged as security for NCDs totaling ₹10,500 million (₹1050 crore). Docon's total shareholding remains at 60.92%.
Read the summary - Medium impact
Thyrocare Q1 FY27 Earnings Call Transcript Released
Thyrocare released its Q1 FY27 earnings call transcript. The company reported a 26% pathology business growth and a 24% consolidated revenue increase. Key initiatives include expanding the lab network, launching specialty diagnostics, and strengthening B2B partnerships. Management aims for specialty diagnostics to form 15-20% of the portfolio in 3-5 years.
Read the summary - Low impact
Thyrocare Resubmits Q1 FY27 Unaudited Financial Results
Thyrocare Technologies Limited resubmitted its unaudited standalone and consolidated financial results for Q1 FY27. Standalone revenue from operations was ₹225.66 crore, with profit after tax at ₹50.17 crore. Consolidated revenue from operations stood at ₹240.02 crore, with profit after tax of ₹52.19 crore.
Read the summary - Low impact
Thyrocare Technologies Ltd. Publishes Newspaper Advertisement for Unaudited Financial Results
Thyrocare Technologies Limited published newspaper advertisements for its unaudited financial results for the quarter ended June 30, 2026. The ads appeared in Navshakti and Business Standard, with a QR code for full results. Results are also on the company website.
Read the summary - Low impact
Thyrocare Technologies Ltd. Releases Post-Results Earnings Call Audio Recording
Thyrocare Technologies Limited has released the audio recording of its earnings conference call held on July 23, 2026, discussing results for the quarter ended June 30, 2026. The transcript will be shared soon.
Read the summary - Medium impact
Thyrocare considers demerger of its radiology business from wholly-owned subsidiary
Thyrocare Technologies Limited's Board has in-principle approved the evaluation of a demerger for its wholly-owned subsidiary, Nueclear Healthcare Limited's, radiology business. The restructuring aims to separate the advanced cancer diagnostics and nuclear medicine operations. Detailed terms will be presented to the Board later, pending regulatory approvals.
Read the summary - Low impact
Thyrocare approves Q1 FY27 results and reappoints Ernst & Young LLP as Internal Auditor
Thyrocare Technologies Limited's Board approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. The Board also re-appointed M/s. Ernst & Young LLP as Internal Auditors for FY 2026-27.
Read the summary - High impact
Thyrocare Q1 FY27 Results: Revenue up 24%, PAT up 34% YoY
Thyrocare Technologies Limited reported Q1 FY27 consolidated revenue of ₹240 crore, up 24.3% YoY. PAT increased by 34.1% to ₹51.33 crore. Standalone revenue grew 26.1% to ₹225.66 crore, with PAT up 39.2% to ₹50.17 crore. Tests conducted rose 28% to 55.2 million, and active franchisees reached 11,730.
Read the summary - High impact
Thyrocare Q1FY27: Revenue surges 24% to ₹240.02 Cr, PAT up 34% to ₹51.33 Cr
Thyrocare Technologies reported Q1FY27 results with consolidated revenue up 24% YoY to ₹240.02 Cr and PAT up 34% YoY to ₹51.33 Cr. The company processed 55.2 million tests, a 28% YoY increase. Thyrocare has expanded into Specialty Diagnostics, starting with Allergy and Genomics.
Read the summary - Low impact
Thyrocare Approves Q1 FY27 Unaudited Results and Re-appoints Ernst & Young LLP as Internal Auditor
Thyrocare Technologies Limited approved its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The Board also re-appointed Ernst & Young LLP as the Internal Auditors for FY 2026-27. The Board meeting was held on July 23, 2026.
Read the summary - Low impact
Thyrocare Schedules Q1FY27 Earnings Conference Call for July 23, 2026
Thyrocare Technologies Limited will host an earnings conference call on July 23, 2026, at 6:00 PM IST. The call will discuss the unaudited financial results for the quarter ended June 30, 2026. Senior management will participate.
Read the summary - Low impact
Thyrocare Technologies Limited: SEBI Reg 74(5) Certificate for Q1FY27
Thyrocare Technologies Limited received a certificate for Q1FY27 under SEBI (Depositories and Participants) Regulations, 2018. Regulation 74(5) is not applicable as all shares are in demat form, and no rematerialization requests were received.
Read the summary - Low impact
Thyrocare Technologies Limited Approves MOA Amendment at 26th AGM
Thyrocare Technologies Limited's Members approved an amendment to the MOA at the 26th AGM on June 30, 2026. The amendments expand the company's business scope to include a wider range of diagnostic services, digital platforms, and medical equipment operations.
Read the summary - Medium impact
Thyrocare Technologies Limited's 26th AGM: All resolutions passed, including dividend declaration.
Thyrocare Technologies Limited's 26th AGM on June 30, 2026, saw the approval of FY26 financial statements and a total dividend of ₹14.00 per equity share (₹7.00 final, ₹7.00 interim). Key approvals included re-appointing Mr. Alok Kumar Jagnani, appointing new auditors, and confirming directors Mr. Gaurav Verma and Mr. Uday Patel Kadam.
Read the summary - Low impact
Thyrocare Announces Final Dividend; Details Tax Deductions for Shareholders
Thyrocare recommended a final dividend of ₹7.00 per share for FY26. The AGM to approve this is on June 30, 2026, with a record date of June 23, 2026. Shareholders must submit tax documents by June 26, 2026, for TDS on dividend distribution.
Read the summary - Low impact
Thyrocare Announces 26th AGM on June 30, 2026, with Dividend Record Date June 23
Thyrocare Technologies Limited will hold its 26th AGM on June 30, 2026. The record date for the final dividend is June 23, 2026, with payment on or before July 29, 2026. E-voting is from June 26 to June 29, 2026. The Annual Report for FY 2025-26 is available online.
Read the summary - Low impact
Thyrocare Submits FY26 Business Responsibility and Sustainability Report
Thyrocare Technologies Limited has submitted its Business Responsibility and Sustainability Report for FY 2025-26. The report details the company's ESG initiatives, operational data, employee welfare measures, and governance practices. It is filed as per SEBI Listing Regulations.
Read the summary - Low impact
Thyrocare Sets Record Date June 23 for Final Dividend Payment
Thyrocare Technologies Limited has set June 23, 2026, as the record date for its final dividend of ₹7 per equity share for FY26. The AGM is on June 30, 2026, with dividend payment expected by July 29, 2026, if approved.
Read the summary - Low impact
Thyrocare Technologies announces 26th AGM on June 30, 2026, to approve FY25-26 Annual Report.
Thyrocare Technologies Limited will hold its 26th Annual General Meeting on June 30, 2026. The meeting will approve the Annual Report and Business Responsibility and Sustainability Report for FY 2025-26. Remote e-voting is available from June 26 to June 29, 2026.
Read the summary - Low impact
Thyrocare Technologies Limited: Notice of IEPF Share Transfer & E-Communication Registration
Thyrocare Technologies Limited announced the transfer of unclaimed dividends and shares to the IEPF by September 23, 2026. Shareholders are urged to register or update their email addresses with DPs for electronic communication. Unclaimed dividends from FY 2018-19 and corresponding shares will be transferred if not claimed by the deadline.
Read the summary - Low impact
Docon Technologies declares no new share encumbrance on Thyrocare in FY26
Docon Technologies, along with its promoter group, has disclosed no new share encumbrances on Thyrocare Technologies Limited (TTL) for the financial year ended March 31, 2026. Previous encumbrances on 60.93% of TTL's shares remain. A bonus issue occurred on December 1, 2025, with a new encumbrance created on those shares.
Read the summary - Medium impact
Thyrocare Q4 FY26 Earnings Call Transcript Released
Thyrocare Technologies released its Q4 FY26 earnings call transcript. The company reported consolidated revenue of ₹224 crore for Q4 FY26, a 20% year-on-year growth. For FY26, consolidated revenue stood at ₹829 crore, up 21%. Profit after tax for FY26 was ₹163 crore, an 81% increase. The company recommended a final dividend of ₹7 per equity share.
Read the summary - Low impact
Thyrocare Releases Audio Recording of Post-Results Earning Conference Call
Thyrocare Technologies Limited has released the audio recording of its earning conference call held on May 12, 2026. The call discussed financial results for the quarter and year ended March 31, 2026. The transcript will be shared soon.
Read the summary - Low impact
Thyrocare Announces Newspaper Publication of Audited Financial Results for Q4FY26
Thyrocare Technologies Limited published its audited financial results for the quarter and year ended March 31, 2026, on May 9, 2026. The results are available in Navshakti and Business Standard, and on the company's website. The disclosure adheres to SEBI regulations.
Read the summary - Low impact
Thyrocare to host Earnings Conference Call on May 12, 2026
Thyrocare Technologies Limited will hold an earnings conference call on May 12, 2026, at 9:00 AM IST to discuss financial results for the quarter and year ended March 31, 2026. Senior management will participate.
Read the summary - Medium impact
Thyrocare Board Approves Dividend, Auditor, Director Appointments & Subsidiary Investment
Thyrocare's Board recommended a final dividend of ₹7.00 per share for FY26, totaling ₹9.33 per share. Price Waterhouse Chartered Accountants LLP appointed as statutory auditors for five years. Rahul Franklin Guha re-appointed as CMD & CEO for five years. Investment up to ₹5.50 crore approved for subsidiary Think Health Diagnostics.
Read the summary - Medium impact
Thyrocare Board Approves Final Dividend, Auditor Appointment, Director Changes, and Subsidiary Investment
Thyrocare's Board recommended a final dividend of ₹7.00 per share for FY26, totaling ₹9.33 including interim dividend. Price Waterhouse Chartered Accountants LLP appointed as statutory auditors for five years. Mr. Rahul Franklin Guha re-appointed as CMD & CEO for five years from May 2027. Two new directors appointed, two resigned. Investment up to ₹5.50 crore in subsidiary Think Health Diagnostics approved.
Read the summary - Medium impact
Thyrocare Board Approves Dividend, New Auditors, Director Appointments, and Subsidiary Investment
Thyrocare recommended a final dividend of ₹7.00 per share for FY26, making the total dividend ₹9.33. Price Waterhouse Chartered Accountants LLP appointed as new statutory auditors for five years. Mr. Rahul Franklin Guha re-appointed as CMD & CEO for five years from May 2027. The company will invest up to ₹5.50 crore in its subsidiary, Think Health Diagnostics.
Read the summary - Medium impact
Thyrocare Board Approves Final Dividend, Auditor Appointment, and Director Changes
Thyrocare's Board recommended a final dividend of ₹7 per share for FY2025-26. M/s. Price Waterhouse Chartered Accountants LLP appointed as Statutory Auditors for five years. Mr. Rahul Franklin Guha re-appointed as CMD & CEO for five years from May 4, 2027. Two directors resigned, and two new additional directors were appointed. The company will invest up to ₹5.50 crore in its subsidiary, Think Health Diagnostics.
Read the summary - Medium impact
Thyrocare Board Approves Final Dividend, Auditor Appointment, Director Changes & Subsidiary Investment
Thyrocare's Board recommended a final dividend of ₹7.00 per share for FY26. M/s. Price Waterhouse Chartered Accountants LLP appointed as Statutory Auditors for five years. Mr. Rahul Franklin Guha re-appointed as CMD & CEO for five years. Investment of up to ₹5.50 crore approved for subsidiary Think Health Diagnostics.
Read the summary - Medium impact
Thyrocare Board Approves Dividend, Auditor Appointment, and Director Changes
Thyrocare's Board recommended a final dividend of ₹7.00 per share for FY26, totaling ₹9.33. Price Waterhouse Chartered Accountants LLP appointed as Statutory Auditors for five years. Mr. Rahul Franklin Guha re-appointed as CMD & CEO for five years. Two new directors appointed, two resigned. Investment of up to ₹5.50 crore approved for a subsidiary.
Read the summary - Medium impact
Thyrocare Board Approves Final Dividend, Auditor Appointment, and Director Changes
Thyrocare recommended a final dividend of ₹7.00 per share for FY26, bringing the total to ₹9.33. M/s. Price Waterhouse Chartered Accountants LLP appointed as statutory auditors for five years. Mr. Rahul Franklin Guha re-appointed as CMD & CEO for five years from May 2027. Mr. Uday Patel Kadam and Mr. Gaurav Verma appointed as Additional Directors. The company will invest up to ₹5.50 crore in its subsidiary, Think Health Diagnostics.
Read the summary - Medium impact
Thyrocare Board Approves Final Dividend, Auditor Appointment, and Director Changes
Thyrocare recommended a final dividend of ₹7.00 per share for FY26. Price Waterhouse Chartered Accountants LLP was appointed as Statutory Auditors for five years. Mr. Rahul Franklin Guha was re-appointed as CMD & CEO. Mr. Uday Patel Kadam and Mr. Gaurav Verma were appointed as Additional Directors. The company will invest up to ₹5.50 crore in its subsidiary, Think Health Diagnostics.
Read the summary - Medium impact
Thyrocare Reports Q4 FY26 Audited Results with Unmodified Opinion
Thyrocare Technologies Limited announced audited standalone and consolidated results for Q4 FY26. Standalone revenue was ₹210.67 crore and PAT ₹43.58 crore. Consolidated revenue was ₹223.95 crore and PAT ₹41.98 crore. The board recommended a ₹7 per share final dividend.
Read the summary - High impact
Thyrocare Q4FY26: Revenue up 20% to ₹223.95 Cr, PAT surges 128% to ₹48.70 Cr
Thyrocare Technologies reported Q4 FY26 consolidated revenue of ₹223.95 crore, up 20% YoY. PAT surged 128% to ₹48.70 crore, and EBITDA grew 31% to ₹75.09 crore. The company processed 59.0 million tests, a 29% YoY increase. For FY26, revenue reached ₹829.04 crore (up 21% YoY), with PAT at ₹162.85 crore (up 81% YoY).
Read the summary - High impact
Thyrocare Q4FY26 PAT Jumps 128% YoY to ₹48.7 Cr on 20% Revenue Growth
Thyrocare reported a 128% YoY jump in consolidated PAT to ₹48.70 crore for Q4FY26, on 20% revenue growth to ₹223.95 crore. FY26 consolidated PAT grew 81% YoY to ₹162.85 crore. Standalone PAT surged 101% YoY to ₹43.58 crore in Q4FY26. Active franchisees increased 15% YoY to ~10,800.
Read the summary - High impact
Thyrocare Board Approves Q4 FY26 Results, Final Dividend, Auditor Appointment, and More
Thyrocare's Board approved Q4 FY26 results and recommended a final dividend of ₹7 per share. Price Waterhouse Chartered Accountants LLP appointed as statutory auditors for five years. Mr. Rahul Franklin Guha re-appointed as CMD & CEO. Investment of up to ₹5.5 crore approved in subsidiary Think Health Diagnostics.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio - Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio